Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oncopeptides AB (publ)
  6. News
  7. Summary
    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oncopeptides : Webcast - Presentation of the Q3 Interim Report 2021

11/19/2021 | 09:04am EST

Oncopeptides will publish its report for the third quarter 2021 on November 24, 2021, and will host a webcast on the same day at 10:00 CET.

Investors, financial analysts and media are invited to participate in this webcast with a QnA session.

The event will be hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation will be held in English.

The webcast will be streamed via this link:
https://tv.streamfabriken.com/oncopeptides-q3-2021.

Phone numbers for participants:

SE: +46 8 505 583 53

UK: +44 333 300 92 61

US: +1 833 823 05 89

Disclaimer

Oncopeptides AB published this content on 19 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 November 2021 14:03:06 UTC.


ę Publicnow 2021
All news about ONCOPEPTIDES AB (PUBL)
01/21ONCOPEPTIDES : Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto
PU
01/21Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market i..
AQ
01/21Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Mar..
CI
01/13Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
AQ
01/13Oncopeptides AB Announces Data from Phase 3 Ocean Study Published in the Lancet Haemato..
CI
01/05Oncopeptides announces year-end cash 2021
AQ
2021Multiple Myeloma Hub continues to provide the latest treatment and research updates in ..
AQ
2021Oncopeptides presents new melflufen data at the Annual American Society of Hematology M..
AQ
2021Oncopeptides publishes Q3 2021 report
AQ
2021Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
More news
Financials
Sales 2021 156 M 16,7 M 16,7 M
Net income 2021 -1 302 M -139 M -139 M
Net cash 2021 187 M 20,0 M 20,0 M
P/E ratio 2021 -0,52x
Yield 2021 -
Capitalization 703 M 75,9 M 75,2 M
EV / Sales 2021 3,31x
EV / Sales 2022 17,7x
Nbr of Employees 321
Free-Float -
Chart ONCOPEPTIDES AB (PUBL)
Duration : Period :
Oncopeptides AB (publ) Technical Analysis Chart | ONCO | SE0009414576 | MarketScreener
Technical analysis trends ONCOPEPTIDES AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 9,34 SEK
Average target price 10,35 SEK
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Stig Anders Jakob Lindberg Chief Executive & Scientific Officer
Annika Muskantor Chief Financial Officer
Per Wold-Olsen Chairman
Fredrik Lehmann Head-Research, Chemistry, Manufacturing & Control
Klaas Bakker Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ONCOPEPTIDES AB (PUBL)11.19%76
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812